Interestingly, GSDME‐deficient melanoma represents defective HMGB1 release, the reduced infiltration of tumor‐associated T cells and activated DCs in response to BRAFi + MEKi treatment, and the more frequent tumor regrowth after drug removal. Here, HMGB1 is linked to melanoma.